WCM Investment Management LLC Boosts Holdings in Repligen Corporation (NASDAQ:RGEN)

WCM Investment Management LLC grew its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,992 shares of the biotechnology company's stock after acquiring an additional 5,906 shares during the period. WCM Investment Management LLC owned 0.18% of Repligen worth $13,740,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Oppenheimer & Co. Inc. purchased a new stake in Repligen in the 4th quarter worth approximately $216,000. Proficio Capital Partners LLC bought a new position in Repligen in the 4th quarter worth about $3,066,000. US Bancorp DE raised its holdings in shares of Repligen by 1.9% in the 4th quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock valued at $1,471,000 after acquiring an additional 190 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Repligen by 89.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,057 shares of the biotechnology company's stock valued at $152,000 after acquiring an additional 499 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Repligen by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,900 shares of the biotechnology company's stock valued at $54,395,000 after acquiring an additional 14,521 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on RGEN. Royal Bank Of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Barclays began coverage on shares of Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. Finally, Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $172.83.

Repligen Trading Up 0.3%

Shares of NASDAQ:RGEN traded up $0.40 on Friday, reaching $127.36. 208,766 shares of the company traded hands, compared to its average volume of 728,834. The stock has a market capitalization of $7.16 billion, a P/E ratio of -283.02, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11. The business's 50-day simple moving average is $126.70 and its 200 day simple moving average is $139.96. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 52 week low of $102.97 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. Repligen's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.28 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.